XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stockholders' Equity (Notes) | 9 Months Ended
--- | ---
Sep. 30, 2017
Stockholders' Equity Attributable to Parent [Abstract] |
Stockholders' Equity Note Disclosure [Text Block] | Stockholders' Equity Common Stock On February 3, 2017, we acquired the HIS business from Pfizer and as partial consideration, we issued 3.2 million unregistered shares of our common stock to Pfizer. The fair value of the common stock was determined based on the closing price of our common shares on the issuance date, discounted to reflect a contractual lock-up period, whereby Pfizer is prohibited from the transfer of the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement (see Note 18: Collaborative and Other Arrangements) or (ii) eighteen months. Treasury Stock In July 2010, our Board of Directors approved a common stock purchase plan to purchase up to $40.0 million of our common stock. This plan has no expiration date. During the three and nine months ended September 30, 2017, we did not purchase any shares of our common stock under the stock purchase plan. As of September 30, 2017, the remaining authorized amount under this purchase plan is approximately $7.2 million. We are currently limited on share purchases in accordance with the terms and conditions of our Senior Note with Pfizer, (see Note 15: Long-Term Obligations). For the nine months ended September 30, 2017, we withheld 27,129 shares of our common stock from employee vested restricted stock units in consideration for $4.0 million in payments made on the employee's behalf for their minimum statutory income tax withholding obligations. Treasury stock is used to issue shares for stock option exercises, restricted stock grants and employee stock purchase plan stock purchases. Accumulated Other Comprehensive Income (Loss) The components of AOCI, net of tax, were as follows (in thousands):
|  | Foreign Currency Translation Adjustments |  | Unrealized Gains on Cash Flow Hedges | Other Adjustments |  | Total
Balance as of December 31, 2016 |  | $ | (21,272 | ) |  | $ | — |  | $ | — |  |  | $ | (21,272 | )
Other comprehensive income (loss) before reclassifications |  | 16,747 |  |  | 1,329 |  | (238 | ) |  | 17,838 |
Amounts reclassified from AOCI |  | — |  |  | (344 | ) | — |  |  | (344 | )
Other comprehensive income (loss) |  | 16,747 |  |  | 985 |  | (238 | ) |  | 17,494 |
Balance as of September 30, 2017 |  | $ | (4,525 | ) |  | $ | 985 |  | $ | (238 | ) |  | $ | (3,778 | )

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration